R292K substitution and drug susceptibility of influenza A(H7N9) viruses

Emerging Infectious Diseases

Volumn 19, Issue 9, 2013, Pages 1521-1524

  Sleeman, Katrina ^a   Guo, Zhu ^a   Barnes, John ^a   Shaw, Michael ^a   Stevens, James ^a   Gubareva, Larisa V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; IC 50; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VIRUS A; INFLUENZA VIRUS A H7N9; MOLECULAR DYNAMICS; NONHUMAN; R292K SUBSTITUTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS ISOLATION;

ANTIMICROBIAL RESISTANCE; ANTIVIRAL RESISTANCE; AVIAN INFLUENZA; H7N9; INFLUENZA; NEURAMINIDASE INHIBITOR; OSELTAMIVIR; R292K; RECOMBINANT NEURAMINIDASE; VIRUSES; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHINA; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE;

EID: 84882648321     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1909.130724     Document Type: Article

References (15)

1. World Health Organization. Global Alert and Response (GAR): human infection with influenza A(H7N9) virus in China. Geneva: The Organization; 2013 [cited 2013 May 9]. http://www.who.int/csr/ don/2013_04_01/en/index.htm.
2. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A(H7N9) virus. N Engl J Med. 2013;368:1888-97. http://dx.doi.org/10.1056/NEJMoa1304459
3. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Preliminary report: epidemiology of the avian influenza A(H7N9) outbreak in China. N Engl J Med. 2013; [Epub ahead of print]. [cited 2013 Jul 15]. http://dx.doi.org/10.1056/NEJMoa1304617
4. Centers for Disease Control and Prevention. Emergence of avian influenza A(H7N9) virus causing severe human illness-China, February-April 2013. MMWR Morb Mortal Wkly Rep. 2013;62:1-5.
5. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17:159-73. http://dx.doi.org/10.3851/IMP2067
6. Okomo-Adhiambo M, Sleeman K, Lysen C, Nguyen HT, Xu X, Li Y, et al. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respi Viruses. 2013; [Epub ahead of print]. http://dx.doi.org/10.1111/irv.12113
7. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol. 1997;71:3385-90.
8. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol. 1998;72:2456-62.
9. Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 2009;81:16-24. http://dx.doi.org/10.1016/ j.antiviral.2008.08.008
10. World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87:369-80.
11. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381:2273-9. http://dx.doi. org/10.1016/S0140-6736(13)61125-3
12. Hurt AC, Nor'e SS, McCaw JM, Fryer HR, Mosse J, McLean AR, et al. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol. 2010;84:9427-38. http://dx.doi.org/10.1128/JVI.00373-10
13. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002;54:79-88. http://dx.doi.org/10.1016/S0166-3542(01)00215-7
14. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 2000;47:1-17. http://dx.doi.org/10.1016/S0166-3542(00)00103-0
15. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002;54:99-111. http://dx.doi.org/10.1016/S0166-3542(01)00214-5